<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Clinical Medicine</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/4E46F45C-B733-4BD2-90E3-678EA01A87C4"><gtr:id>4E46F45C-B733-4BD2-90E3-678EA01A87C4</gtr:id><gtr:firstName>Geraldine</gtr:firstName><gtr:otherNames>Martina</gtr:otherNames><gtr:surname>Gillespie</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0501011"><gtr:id>5C557E4A-006E-4D68-A91C-8C7E40E507A6</gtr:id><gtr:title>Aspects of CD8+ T cell and NK cell recognition that impact on MHC class I associations with HIV-1 disease progression</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0501011</gtr:grantReference><gtr:abstractText>Over 50% of the 40 Million people estimated to be infected with HIV-1 live in sub-Saharan Africa alone. With only a small proportion of developing countries having access to the anti-retroviral therapies readily available in the Western world, an alternative approach is urgently required to control the spread of this virus. One promising strategy is the production of a vaccine to either prevent infection and/or augment immunity against HIV-1 during disease. Cells of the immune system, namely CD8+ T lymphocytes, effectively control the growth of HIV-1, and many vaccines in current clinical trials are designed to evoke CD8+ T cell mediated immunity.The interaction between this virus and the host s immune system is complex, however, and the level of viral control is variable in HIV-1 infected individuals. This, in turn, makes it difficult to design a truly effective HIV vaccine. Major Histocompatibility Complex (MHC) class I molecules represent important host factors that influence disease outcome - these molecules direct the CD8+ T cell responses against HIV-1, and therefore influence disease severity. By studying the fine details of diverse CD8+ T cell responses in distinct HIV-1 infected patient groups I hope to identify the reasons why some CD8+ T cell responses are more effective than others in controlling the replication of HIV-1. Certain MHC class I molecules also interact with different cells of the immune system, namely Natural Killer (NK) cells, and this also impacts on disease dynamics in HIV-1 infection. I also wish to study aspects of NK and MHC interactions that might explain this phenomenon, as this could influence the design and implementation of future vaccine regimens.</gtr:abstractText><gtr:technicalSummary>The natural history of HIV-1 infection is extremely heterogeneous, reflecting the complex interplay between viral and host genetic determinants that influence disease outcome. Of the major host factor influencing HIV-1 disease progression, the MHC class I loci is consistently described. MHC class I molecules select the repertoire of viral epitopes presented to CD8+ T cells and shape the immune response against HIV. Defining precise factors that explain influence of the MHC class I molecules on long term survival is crucial to our understanding of HIV-1-mediated disease pathogenesis, and to further the design of effective CD8+ T cell targeted vaccines and management of vaccination regimens. 
The MHC class I molecules B*27 and B*57 represent favourable host genetic determinants that associate with slower disease progression. Whilst strong CD8+ T cell responses to a single and highly conserved immunodominant epitope account for the association of HLA B*27 with prolonged survival, the correlates relating HLA B*57 to favourable outcome are complex, and distinct B*57-restricted CD8+ T lymphocyte responses appear differentially effective in controlling HIV-1 replication. I wish to study features of CD8+ T cell recognition that might explain this phenomenon, including aspects of T cell receptor usage and biophysical parameters, in addition to qualitatively assessing individual B*57-restricted immune responses. I will also investigate whether the efficacy of B*57-restricted responses relates to features of antigen processing and presentation. 
The influence of innate immune system on MHC class I associations with prolonged survival in HIV-1 infection has also be demonstrated, specifically, the synergistic association of a subset of MHC class I Bw4 molecules and an NK receptor from the Killer Inhibitory receptor (KIR) gene family called KIR3DS1. KIRs comprise a distinct group of MHC class I receptors, and are expressed on Natural Killer (NK) cells and a subset of T lymphocytes. They comprise both inhibitory and stimulatory receptors, of which KIR3DS1 is a putative stimulatory receptor, and allele of the inhibitory KIR3DL1 molecule. It is imperative that we define the relationship between KIR3DS1 and the associating MHC class I molecules, so as to understand natural disease pathogenesis and to elucidate whether the KIR haplotype of vaccine recipients should be considered when designing HIV-1 vaccine regimens. I aim to determine the ligand specificity of KIR3DS1, and to evaluate features of KIR3DS1 recognition that might explain its association with prolonged survival during HIV-1 infection.</gtr:technicalSummary><gtr:fund><gtr:end>2009-03-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>323112</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School visit:Oxford</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>3411C8C5-15C3-4A33-B0F8-31EF4B59AF5F</gtr:id><gtr:impact>28 year 6 students were taught about immune recognition

Got the attention of 10-11 year olds-there were interested in a topic that is not normally introduced in primary schools</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Mary Goodger Award (University of Oxford)</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>6614BBA1-7261-40B7-826F-61C92F8D0B4A</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/558A81BE-0A4F-4160-8CB5-8A19F73A9537"><gtr:id>558A81BE-0A4F-4160-8CB5-8A19F73A9537</gtr:id><gtr:title>Functional differences exist between TNFa promoters encoding the common -237G SNP and the rarer HLA-B*5701-linked A variant.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6756197ac615678a2fefef10236a908e"><gtr:id>6756197ac615678a2fefef10236a908e</gtr:id><gtr:otherNames>Simpson PD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0A0BE4E9-14D2-4B3B-AA64-7A96AE2A20A2"><gtr:id>0A0BE4E9-14D2-4B3B-AA64-7A96AE2A20A2</gtr:id><gtr:title>An early HIV mutation within an HLA-B*57-restricted T cell epitope abrogates binding to the killer inhibitory receptor 3DL1.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4657e715e0a0f585fce086332255e435"><gtr:id>4657e715e0a0f585fce086332255e435</gtr:id><gtr:otherNames>Brackenridge S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4A9B8D01-E7D1-41BA-9340-78A6E9603DF5"><gtr:id>4A9B8D01-E7D1-41BA-9340-78A6E9603DF5</gtr:id><gtr:title>Immune Activation and HIV-Specific CD8(+) T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers.</gtr:title><gtr:parentPublicationTitle>AIDS research and human retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0bc7ff336c3b17ceb7faeb592ebfade1"><gtr:id>0bc7ff336c3b17ceb7faeb592ebfade1</gtr:id><gtr:otherNames>Ganesh A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0889-2229</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/16F0C240-FAB8-4FBD-83E6-376EF3FAB8AD"><gtr:id>16F0C240-FAB8-4FBD-83E6-376EF3FAB8AD</gtr:id><gtr:title>Structural features underlying T-cell receptor sensitivity to concealed MHC class I micropolymorphisms.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d074abc03c715ec0a4b00eddac6d3810"><gtr:id>d074abc03c715ec0a4b00eddac6d3810</gtr:id><gtr:otherNames>Stewart-Jones GB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0501011</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>